Effect of the DPP-4 inhibitor, saxagliptin on glucose variability in type 2 diabetes patients with Chronic kidney disease
- Conditions
- Type 2 diabetes patients with CKD
- Registration Number
- JPRN-UMIN000026644
- Lead Sponsor
- ihon University Itabashi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Not provided
1. Patients who have history of hypersensitivity to saxagliptin or the other dpp-4 inhibitors 2. Patients who have history of administration of incretin-related drugs within 4 weeks 3. Patients who changed anti-diabetic drugs, diet thrapy or exercise thrapy within 4 weeks 4. Patients who have end stage renal disease undergoing maintenance dialysis, or after renal transplantation 5. Patients who have history of severe ketosis, diabetic coma, or precoma within 6 months 6. Patients who have history of cancer within 5 years 7. Patients who have liver disfunction with AST or ALT>=3 x upper limit of normal 8. Patients who experienced severe traumatotherapy requiring surgery or surgery with general anesthesia within 6 months 9. Women who is pregnant or planned to become pregnant 10. Patients who are considered not eligible for the study by the attending doctor due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Mean Amplitude of Glycemic Excursions from baseline to week 4 after the start of administration
- Secondary Outcome Measures
Name Time Method Change in glucose variability and biomakers from baseline to week 4 after the start of administration